

*Research Article***Effect of a Hydrogen Sulfide Donor on Skeletal Muscle Contraction and Fatigue in Adult Male Albino Rats****Mariam Y. Ibrahim, Walaa H. Nazmy, and Merhan M. Ragy**

Department of Medical Physiology, Minia Faculty of Medicine

**Abstract**

**Background:** In skeletal muscles, the role of hydrogen sulfide (H<sub>2</sub>S) in contraction has not been fully investigated although impaired formation may be involved in chronic fatigue syndrome; therefore we aimed to study this role. **Methods:** 24 adult male albino rats were classified into 4 groups; injected intraperitoneally (i.p.) with a single dose of the following: **control;** injected with saline (vehicle), **L-NAME treated;** injected with 20 mg/Kg body weight of N<sup>G</sup> – nitro-L- arginine methyl ester (L-NAME) as nitric oxide synthase (NOS) inhibitor; **Sodium hydrosulfide (NaHS) treated;** injected with NaHS as H<sub>2</sub>S donor, at a dose of 100 μmol/kg body weight; **NaHS + L-NAME treated;** rats were coadministered both chemicals in the same previous doses. The right intact gastrocnemius was stimulated by low frequency (LF) electric current 30 min. after injection and subtetanic contractions were recorded till the force declined to 50% of the peak force, while the left gastrocnemius was resting (control). Both gastrocnemius muscles were then excised and assayed biochemically and mechanically. **Results:** NaHS significantly increased the peak force, and delayed the time till 50% fatigue with improving biochemical conditions; decreased lipid peroxides, increased nitric oxide, and creatine kinase activity. The reverse occurred with L-NAME and was associated with increased muscle lactate. Given together, NaHS could significantly, but partially antagonize the fatiguing effects of L-NAME. **Conclusion:** NaHS improves muscle fatigue even when nitric oxide synthesis is blocked indicating that the effect is not NO dependent. It could be promising in fatigue syndromes especially those associated with NO deficiency as myopathies.

**Key Words:** Hydrogen Sulfide donor, skeletal muscle contraction, fatigue, NO, L-NAME, creatine kinase.

**Introduction**

“Muscle fatigue” is defined as a drop in physical work capacity *i.e.* reduced force or power production in response to contractile activity<sup>(1)</sup>. Fatigue is a common symptom of numerous acute and chronic diseases, including myopathies, neurodegenerative diseases, metabolic syndrome and chronic debilitating diseases like cancer<sup>(1)</sup>.

Skeletal muscle fatigue is multifactorial. Defective neuromuscular transmission, failure of excitation-contraction coupling (EC) mechanism, failure of mitochondrial oxidative mechanism with development of oxidative stress and depletion of energy stores could be reasons<sup>(1)</sup>.

Nitric oxide (NO); is the endothelium derived relaxation factor that plays an important role in vascular smooth muscle

relaxation and regulation of muscle blood flow during activity. In physiological concentrations, it increases muscle blood flow during activity, acts as an antioxidant, and postpones muscle fatigue. However, its production in excessive concentrations under abnormal conditions by inducible nitric oxide synthase (iNOS) increases the formation of the most toxic free radical peroxynitrite and accelerates muscle fatigue. On the other hand, reduced nitric oxide synthesis in skeletal muscles is a pathophysiological mechanism contributing to chronic fatigue syndrome<sup>(2)</sup>.

Hydrogen sulfide (H<sub>2</sub>S) was thought for hundreds of years to be a toxic gas that smelled like rotten eggs, but the gas is now believed to be a molecule involved in intensive physiological and pathological processes<sup>(3)</sup>. Cystathionine gamma lyase, 3-

mercaptopyruvate sulfurtransferase ( $\gamma$ -MST) and cysteine aminotransferase (CAT) can produce H<sub>2</sub>S in different tissues<sup>(1)</sup>. H<sub>2</sub>S has been found to be involved in protecting the heart against acute myocardial infarction<sup>(2)</sup> and ischemia/reperfusion injury, regulating blood pressure<sup>(3)</sup>, mediating smooth-muscle relaxation<sup>(4)</sup> and inhibiting insulin release and renin activity<sup>(5,6)</sup>.

In skeletal muscles, the role of H<sub>2</sub>S in contraction has not been fully investigated although it was hypothesized that impaired formation may be involved in chronic fatigue syndrome<sup>(7,8,9)</sup>. Therefore, this work was designed to study the effect of an H<sub>2</sub>S donor; sodium hydrosulfide (NaHS) on skeletal muscle contraction and fatigue in adult male albino rat gastrocnemius muscle and the possible interaction with nitric oxide.

## Material and Methods

### I. Animals:

Adult male albino rats from the local strain, weighing 180-200 grams were used in this study. Rats were housed at room temperature with natural light/dark cycles for one week acclimatization to lab conditions. Rats were fed a standard diet of commercial rat chow and tap water *ad libitum* until the time of the experiment. All the experimental procedures were approved by the local animal care committee in Minia Faculty of Medicine, Minia University, Egypt.

Rats were divided into the following equal groups (7 rats each):

1- **Control group**; where rats were injected with saline solution (0.9% sodium chloride; NaCl), intraperitoneally (i.p.),

2- **L-NAME treated group**; in which each rat was injected with a single dose of 20 mg/Kg body weight i.p. of L-NAME as a nitric oxide synthase (NOS) inhibitor<sup>(10)</sup>.

3- **NaHS treated group**; in which each rat was administered NaHS as an H<sub>2</sub>S donor, i.p. at a dose of 100  $\mu$ mol/kg body weight<sup>(11)</sup>.

4- **L-NAME+ NaSH treated group**; in which each rat was administered both L-NAME and NaHS at the same dose and route as in group 2- and 3-.

Both L-NAME and NaHS were purchased from Sigma Co. and were dissolved in saline just before injection. The different injections were given 30 min. prior to electrical stimulation of the gastrocnemius muscle and the dosing volume was kept at 1 ml/100 g body weight.

### II. Experimental protocol:

#### - Electric stimulation of the right gastrocnemius muscle:

This was done in each rat according to the method of *MacIntosh and Gardiner*<sup>(12)</sup>. Under urethane anesthesia (1.0 g/kg; i.p.), rats were fixed to a dissection board, the skin of both hind limbs was incised longitudinally from the calcaneus to the back of the knee, the gastrocnemius was exposed, the right tendoachillis was tied with silk, cut and fixed to a force transducer (**Bioscience, Holliston, MA, USA**). The manipulation avoided severing the vascular supply of the muscle, aligned the muscle with the transducer, and optimum muscle length that gives the maximal force was adjusted by moving the transducer and when reached it was measured with a tape (L cm). Silver electrodes were directly applied to the right gastrocnemius muscle and connected to a stimulator (**Bioscience, Holliston, MA, USA**). The voltage used was 0.5 V higher than the lowest voltage that produced maximal twitch amplitude (maximal voltage), and the pulse width was set at 0.5 ms. We used low frequency (LF) stimulus (10 Hz) to allow incomplete tetanus with incomplete relaxation allowing for ischemia/reperfusion, and to simulate natural contractions inside the body. The muscle was kept moist all the time with continuous dripping of saline at 37°C. While the right gastrocnemius muscle was the experimental muscle, the left was left unstimulated as control. Previous studies have shown no significant biochemical differences between both sides in the tested parameters at rest<sup>(13)</sup>. The force of contraction was recorded on a calibrated chart of the oscillograph (**Bioscience, USA**). The force of contraction increased gradually to a maximum level, and then decreased gradually thereafter. The experiment was terminated by cessation of electric stimulation when the force of contraction declined to 20% of the maximal

force reached (90% fatigue). Immediately, the gastrocnemius muscles were excised, weighed and placed in liquid nitrogen until biochemically assayed. The following parameters were determined:

- **The maximal force (F)** reached was determined from the calibrated chart.
- **The time till 90% fatigue:** was determined from the start of stimulation till 90% fatigue using the speed of the chart recording.
- **The cross sectional area of the muscle:** This was done considering the muscle as a cylinder of measured length and an average density of  $1.06 \text{ g/cm}^3$ , the cross sectional area is calculated according to *Eu et al.*<sup>(14)</sup>;  
**Cross sectional area (A;  $\text{cm}^2$ ) = muscle weight (g) / [density x length (cm)]**
- The force/ unit surface area of the muscle was calculated by dividing F/A.

#### - **Biochemical analysis:**

For NO and lipid peroxide determination, known weight of gastrocnemius muscle was homogenized in cold saline, centrifuged and the supernatant was used for:

- **Determination of muscle nitric oxide:** Muscle NO was determined using a nitrite assay kit (Biodiagnostic, Egypt) for the colorimetric determination of NO based on the enzymatic conversion of nitrate to nitrite; the stable degradation products of NO by nitrate reductase. The reaction is followed by addition of Griess reagent to the muscle homogenate to convert nitrite into a deep purple azo compound; the absorbance of which is read at 540 nm using a spectrophotometer (**spectronic 2000, Bausch and Lomb, Rochester, NY, USA**). Concentrations were calculated from a standard curve made using sodium nitrite solution of different concentrations<sup>(14)</sup>.

- **Determination of total lipid peroxides:** We used the thiobarbituric acid method described by *Ohkawa et al.*<sup>(15)</sup>. In brief; malondialdehyde (MDA) breakdown products of lipid peroxides in muscle homogenates form colored complexes with thiobarbituric acid that are extracted using n-butanol/pyridine, and the absorbance was read at 532 nm using the spectrophotometer. Concentrations were calculated from a standard curve made using 1,1,3,3-tetramethoxypropane (TMP).

- **Determination of muscle creatine kinase (CK) activity:**

Known weights of gastrocnemius muscle samples were rinsed in phosphate-buffered saline, pH 7.4, to remove blood, homogenized in potassium phosphate, pH 7.0, buffer, centrifuged for 10 minutes at 4°C using a cooling centrifuge, and the cleared supernatant was used for the assay. We used Sigma Diagnostic (St. Louis, MO) assay kit. The principle according to kit's reference<sup>(11)</sup> that total CK activity was determined by using a hexokinase/glucose-6-phosphate dehydrogenase – coupled enzyme system which ultimately yields reduced NADP (NADPH) proportionate to CK activity. The rate of increased absorbance at 340 nm due to production of NADPH by the CK activity was determined. One unit of CK is the amount of enzyme that will transfer  $1.0 \mu\text{mole}$  of phosphate from phosphocreatine to ADP per minute at pH 7.0.

- **Determination of muscle lactate:**

Known weights of gastrocnemius muscle were excised and homogenized in 5 mL of distilled water. Then, 4 mL of 10% trichloroacetic acid was added and, after mixing, tubes were incubated 5 min at 4°C. Immediately afterwards, they were centrifuged at  $2000 \times g$  for 10 min and the supernatants were collected and assayed for lactic acid using the Sigma lactate colorimetric assay kit<sup>(17)</sup>.

### III. Statistical Analysis

The results were expressed as the mean  $\pm$  standard error of the mean (SEM). Statistical analysis of the mean differences between groups was performed using one way ANOVA followed by Tukey-Kramer multiple comparisons tests using InStat, GraphPad Software (version 4, San Diego, USA). Values of  $P < 0.05$  were considered significant.

### Results

1- **Mechanical changes of the right (stimulated) gastrocnemius muscle of the different groups (table 1).**

- Low Frequency (LF) stimulation of the right gastrocnemius muscle of rats of the control group produced peak force of contraction of  $29 \pm 2 \text{ g/cm}^2$  cross sectional

area CSA, then gradual progressive decline in muscle power achieving 50% fatigue after  $10 \pm 6$  sec.

- While L-NAME produced a significant shortening (acceleration) of the time till 50% fatigue as compared to the control group, administration of the H<sub>2</sub>S donor; NaHS produced the opposite effect and significantly delayed the onset of fatigue. When combined, NaHS opposed the rapid onset of fatigue produced by L-NAME and significantly delayed its onset. The time reached was insignificant from that of the control group.

- Regarding the peak force of contraction, the lowest value was recorded in L-NAME group, while, the highest value was achieved in NaHS group. Both were significantly different from control level. When co-administered, NaHS partially improved the L-NAME inhibition, but the level reached was still significantly lower than the control group.

**2- Effect of L-NAME and NaHS treatments alone or combined on tested biochemical parameters of the right (stimulated) and left (resting) gastrocnemius muscles of the different groups.**

**Table (1) shows that:**

- Compared with the control group, NO levels in resting limbs were significantly lower in L-NAME treated groups (either alone or combined with NaHS). Administration of the H<sub>2</sub>S donor; NaHS did not produce any significant change in muscle NO content as compared to the control level.

- Regarding muscle lipid peroxides (LP) content in resting limbs, L-NAME alone failed to produce any significant change from the control, while NaHS treatment significantly lowered muscle LP than that of the control group either alone or combined with L-NAME.

- Low frequency (LF) stimulation produced significant higher muscle NO contents in all groups as compared to their corresponding resting limbs. The gastrocnemius of the

stimulated limb of L-NAME group showed the lowest NO level, while the highest NO level was achieved in NaHS group. In the stimulated limb of the combined group, NaHS significantly attenuated the L-NAME induced inhibition on NO synthesis, but partially since NO level was significantly higher than that of the corresponding L-NAME, but it was still significantly lower than that of the corresponding control.

- Muscle LP contents in the stimulated limbs were significantly higher than their corresponding resting limbs in all groups. Comparing the differential effect of treatments used, L-NAME significantly increased while NaHS significantly decreased LP. NaHS partially attenuated the increased level produced by L-NAME and all measures were significantly different from the control group.

**Table (2) shows that:**

- In resting limbs, muscle lactate was significantly higher than that of control group only in the L-NAME group; **figure (1)**. While, creatine kinase (CK) activity was significantly lower in L-NAME treated group than that of the control group, NaHS treatment had no significant effect. Combined administration of NaHS with L-NAME partially reversed the inhibitory effect of L-NAME on the enzyme activity and caused a significant higher level than that of L-NAME alone, but it was still significantly lower than that of the control; **figure (2)**.

- Muscle lactate concentrations of the stimulated limbs of all groups also showed significantly higher lactate levels than their corresponding resting limbs. NaHS did not significantly change the level as compared to that of stimulated limb of control group while L-NAME significantly increased it. NaHS could partially prevent the increase in muscle lactate produced by L-NAME, however, the level remained significantly higher than that of the control group; **figure (1)**.

**Table (1): Mechanical and biochemical parameters of the right (stimulated) and left (resting) gastrocnemius muscles of the different studied groups.**

Groups		Control		L-NAME		NaHS		NaHS + L-NAME	
		Rest. limb	Stim. limb	Rest. limb	Stim. limb	Rest. limb	Stim. limb	Rest. limb	Stim. limb
<b>Parameters</b>	<b>Time until 50% fatigue (s)</b>		80±6		76±0.4		140±7.3		100±6.2
	% change from control				-22°		+71°		+18
	% change From L-NAME				-		+12.*		+02*
	% change From NaHS				-		-		-31#
<b>Peak force of contraction (g/cm<sup>2</sup> CSA)</b>			29±2		14±1.8		43±2.8		21±1.9
	% change from control				-52°		+48°		-28°
	% change From L-NAME				-		+20.7*		+0.*
	% change From NaHS				-		-		-51#
<b>At 50% Fatigue</b>	<b>NO (µg/g wet weight muscle)</b>	20±1.0	33±3.6	0.7±0.8	9.3±0.7	18.4±2.1	40.7±3.9	6.0±0.7	14.3±1.8
	% change From:								
	-Resting limb		+70°		+76°		+148°		+120°
	-Correspond. control			-72°	-71.8°	-8	+38°	-78°	-57°
-Correspond. L-NAME				-	+229*	+39.*	+17	+04*	
-Correspond. NaHS				-	-	-	-70#	-79#	
<b>Lipid peroxides (µmol/g wet weight muscle)</b>		11±0.2	24±1.9	10.2±0.8	47.6±3.8	0.4±0.6	13±0.11	6.7±0.4	33±2.7
	% change From:								
	-Resting limb		+118°		+377°		+141°		+432°
	-Correspond. control			-7	+98°	-51°	-46°	-44°	+38°
-Correspond. L-NAME				-	-47*	-73*	-39*	-31*	
-Correspond. NaHS				-	-	-	+10	+104#	

Data are expressed as mean ± SEM of 7 rats in each group. (Rest.:Resting, Stim.:Stimulated)  
 ●: Significant from resting limb. ○: Significant from corresponding limb of control group.  
 \*: Significant from corresponding limb of L-NAME group. #: Significant from corresponding limb of NaHS group.

Finally, LF stimulation produced significant higher creatine kinase activity in the stimulated limbs of all groups when compared with their corresponding non stimulated limbs. NaHS treatment did not produce any significant change in creatine kinase (CK) activity when compared to the control group. On the other hand, L-NAME

treatment significantly lowered it. When NaHS was combined with L-NAME, NaHS could partially reverse the inhibitory effect of L-NAME on CK activity which became significantly higher than L-NAME alone, but was still significantly lower than the level of the control group; **figure (2)**.


**Table (2): Lactate concentration and creatine kinase activity changes in the right (stimulated) and left (control) gastrocnemius muscles of the different studied groups.**

Parameters		Groups		Control		L-NAME		NaHS		NaHS + L-NAME	
		Rest. limb	Stim. limb	Rest. limb	Stim. limb	Rest. limb	Stim. limb	Rest. limb	Stim. limb	Rest. limb	Stim. limb
At 60% Fatigue	<b>Muscle lactate (<math>\mu\text{mol/g}</math> wet weight muscle)</b>	$0.70 \pm 0.05$	$0.91 \pm 0.05$	$0.83 \pm 0.07$	$1.17 \pm 0.08$	$0.71 \pm 0.03$	$0.87 \pm 0.06$	$0.74 \pm 0.06$	$1.3 \pm 0.08$		
	% change from:										
	Resting limb		+40*	-	+100*	-	+43*	-	+76*		
	Correspond. control		-	+28 <sup>o</sup>	+87 <sup>o</sup>	-7	-4	+14	+43 <sup>o</sup>		
	Correspond. L-NAME		-	-	-	-27*	-49*	-11	-24*		
	Correspond. NaHS		-	-	-	-	-	+21	+49#		
	<b>Creatine kinase (U/100 mg wet weight muscle)</b>	$37 \pm 1.2$	$48 \pm 2.9$	$12 \pm 0.8$	$16.4 \pm 1.8$	$37 \pm 2.1$	$50 \pm 3.0$	$19.2 \pm 1.4$	$38 \pm 2.9$		
	% change from:										
	Resting limb		+33*	-	+37*	-	+49*	-	+98*		
	Correspond. control		-	-17 <sup>o</sup>	-76 <sup>o</sup>	+3	+10	-47 <sup>o</sup>	-21 <sup>o</sup>		
Correspond. L-NAME		-	-	-	+20.8*	+230*	+70*	+132*			
Correspond. NaHS		-	-	-	-	-	-48#	-31#			

Data are expressed as mean  $\pm$  SEM of 6 rats in each group.

●: Significant from resting limb. ○: Significant from corresponding limb of control group.

\*: Significant from corresponding limb of L-NAME group. #: Significant from corresponding limb of NaHS group.




**Figure (1): Changes in muscle lactate content ( $\mu\text{mol/g}$  wet weight muscle) in different studied groups.**

Data are expressed as mean  $\pm$  SEM of 6 rats in each group.

●: Significant from resting limb. ○: Significant from corresponding limb of control group.

\*: Significant from corresponding limb of L-NAME group. #: Significant from corresponding limb of NaHS group.



**Figure (2): Changes in muscle CK activity (U/10 mg wet weight muscle) in different studied groups.**

Data are expressed as mean  $\pm$  SEM of 7 rats in each group.

●: Significant from resting limb. ○: Significant from corresponding limb of control group.

\*: Significant from corresponding limb of L-NAME group. #: Significant from corresponding limb of NaHS group.

## Discussion

In the present study, an attempt was made to study some of the factors contributing to skeletal muscle fatigue in the right gastrocnemius muscle of intact male albino rats under different treatment conditions as compared to the left resting gastrocnemius. LF electric current stimulation produced subtetanic contraction allowing ischemia/reperfusion that generates high concentrations of free radicals. A significant increase in NO, lipid peroxides, muscle lactate and CK activities were present at 90% fatigue in the stimulated gastrocnemius muscle as compared to the resting one of the control group.

Nitric oxide (NO), is formed from the amino acid L-arginine *via* nitric oxide synthases (NOS); neuronal (nNOS), and endothelial (eNOS) linked to dystrophin protein of the muscle cytoskeleton close to muscle blood vessels, where it regulates muscle blood flow during rest and contraction<sup>(17)</sup>. Stimulation of e-NOS and n-NOS occurs during muscle contraction probably by increasing cytosolic  $Ca^{2+}$  since they are  $Ca^{2+}$  dependent<sup>(18)</sup>. NO not only increases muscle blood flow during contraction, but also through stimulation of peroxisome proliferator activator receptor- $\gamma$

cofactors can induce mitochondrial proliferation (mitochondrial biogenesis), oxidative enzymes of the citric acid cycle and  $\beta$ -oxidation of fatty acids which provide the energy sources during contraction<sup>(19)</sup>. NO also through nitrosylation of glucose transporter proteins can enhance glucose extraction by contracting skeletal muscle independent of insulin<sup>(20)</sup>.

Basal levels of peroxides as markers of reactive oxygen species (ROS) were detected in the resting gastrocnemius muscle of this work and could be produced by the respiratory chain complex of the mitochondria or in the cytosol *via* xanthine oxidase, NADPH oxidases, and phospholipase  $A_2$  that generate superoxide radicals<sup>(21)</sup>. Physiological increase in ROS generation during muscle contraction is essential for excitation-contraction (EC) coupling through oxidation of the thiol (-SH) groups of calcium sensor channels and other ion channels maintaining excitability<sup>(22)</sup>, facilitates glucose uptake through an AMP-activated glucose transporter, and activates nuclear peroxisome proliferator activator receptor alpha (PPAR $\alpha$ ) to enhance fatty acid uptake and  $\beta$ -oxidation. In addition, free radicals maintain Redox homeostasis in the muscle

by feedback stimulation of antioxidant defense mechanisms<sup>(74,75)</sup>. However, excess ROS production produces the reverse, especially excessive oxidation of myosin heads with failure of EC coupling, resulting in fatigue<sup>(77)</sup>. NO is a double faced coin. In physiological concentrations, it is a scavenger of ROS, but in greater concentrations it forms the cytotoxic peroxynitrite radical and can contribute to fatigue<sup>(77)</sup>.

Creatine kinase (CK) catalyzes the reaction; Creatine phosphate + ADP + H<sup>+</sup> ↔ Creatine + ATP, in either direction, thus ensures proper channeling of high energy phosphate between the creatine/phosphocreatine and the ADP/ATP systems to ensure adequate energy supply for the skeletal muscle at rest and during activity. In the mitochondria, Mitochondrial CK couples oxidative phosphorylation of the respiratory chain to creatine phosphate formation i.e. shift to the left of the above reaction, while Cytosolic CK is confined to the sites where it is in close proximity to ATPase as in myosin M line near the heads of myosin, the sarcoplasmic reticulum and the sarcolemma and shifts the reaction to the right<sup>(78,79)</sup>. The significant high CK level in the gastrocnemius of the stimulated limb of the control group in this study ensures a maintained ATP supply at the expense of CP and is compatible with *McMullen et al.*<sup>(77)</sup>. However, CK activity can also contribute to muscle fatigue especially under oxidative stress conditions when the breakdown of CP results in excessive accumulation of inorganic phosphate (P<sub>i</sub>). P<sub>i</sub> interferes with the cross bridge cycle, and could diffuse to sarcoplasmic reticulum and precipitates Ca<sup>2+</sup> according to previous researches<sup>(79,78)</sup>.

Muscle lactate increased in the muscle of the stimulated limb as compared with the contralateral relaxing limb. Muscle lactate system' contribution to ATP production is minimal, but it is essential for reoxidation of NADH<sup>+</sup> to NAD<sup>+</sup> ensuring continuous oxidation. It is a marker of anaerobic glycolysis. Because this system generates lactate and H<sup>+</sup> in equimolar concentrations and it was difficult to measure intracellular H<sup>+</sup>, lactate was therefore incriminated as the cause of fatigue; however this concept is a

subject of greater debate. Researches, in the past few years, proved that lactic acid accumulation during contraction of skeletal muscle keeps muscle excitability, EC coupling, and force production by decreasing chloride permeability through inhibiting voltage gated chloride channels in the T tubules thus preventing hyperpolarization of overactivity<sup>(73,80)</sup>. Previous concepts ascribed fatigue to increased H<sup>+</sup> and not lactate that suppress the contractile machinery including, Ca<sup>2+</sup> release and binding to troponin C and cross bridge cycling in addition to altering enzyme activity particularly phosphorylases of glycogenolysis and phosphofructokinase of glycolysis and hence block metabolic oxidative pathways<sup>(73,81)</sup>.

In the present work, blocking NO synthesis by L-NAME injection significantly reduced the peak force, shortened the time till 90% fatigue, lowered NO, and CK activity, but increased lipid peroxides and muscle lactate. These results agree with *Tidball and Henricks*,<sup>(82)</sup> who found that patients who lack NO as in Duchene myopathy suffer from muscle weakness and atrophy due to low muscle blood flow rate. The absent physiological role of NO in muscle contraction and the loss of its ROS scavenging function was associated with increased lipid peroxidation and accelerating fatigue according to previous research<sup>(82)</sup>. The highest levels of lactate obtained in this L-NAME group is a proof of the extreme hypoxic conditions due to lack of the vasorelaxant effect of NO. Furthermore, under such hypoxic or oxidative stress conditions, ATP consumption should be switched off to prevent its depletion to critical levels. This is mediated by inhibiting CK activity by a phosphorylating protein enzyme (AMP-activated protein kinase; AMPK) or by increased leakage from the muscle membrane according to previous researches<sup>(78,79)</sup>.

In the present study, i.p. injection of sodium hydrosulfide; as an exogenous donor of H<sub>2</sub>S not only increased the peak force of contraction, but also delayed the onset of 90% fatigue in the stimulated gastrocnemius muscle. This could be ascribed to decreased ROS as evidenced by a



significant lower lipid peroxide level. Muscle lactate and CK activity were not significantly different from the control group. H<sub>2</sub>S is endogenously produced in different body tissues and plays a physiological role most probably as antioxidant. It is also produced in skeletal muscle; however its role in contraction and fatigue was not fully investigated although it was hypothesized to be incriminated in chronic fatigue syndrome<sup>(7)</sup>. Therefore this study aimed to study this effect. The increased peak force and delayed fatigue found in the present study could be ascribed to the vasorelaxant effect of H<sub>2</sub>S which increases blood flow according to previous results<sup>(8,9)</sup>. Furthermore, NaHS/H<sub>2</sub>S could modify calcium channels by sulfhydration of channel proteins, an effect that protects channel proteins against oxidative damage by ROS according to *Zhang et al*<sup>(10)</sup>. This could keep adequate calcium ions for excitation/contraction coupling. These results are consistent with previous researches<sup>(10,11)</sup> who found that in a rat model of ischemia/reperfusion of the hind limb skeletal muscles, preischemic delivery of hydrogen sulfide limits ischemia-reperfusion injury-induced cellular damage and reduced the apoptotic index in *in vitro* myotubes and *in vivo* skeletal muscles. This suggests that, when given in the appropriate dose, this molecule may have significant therapeutic applications in multiple clinical fatigue syndromes.

NaHS, in this study partially but significantly improved the fatiguing effect of L-NAME and improved the mechanical and metabolic conditions of the muscle. This may be ascribed to the role of NaHS/H<sub>2</sub>S in scavenging ROS, minimizing oxidative stress, and improving blood flow. A vasorelaxant effect of H<sub>2</sub>S through activation of voltage-sensitive potassium channels and not NO dependent was found by *Kohn et al.*<sup>(12)</sup> and is compatible with the improved conditions in the combined group. Improved oxidative stress state is the cause of decreased muscle lactate and increased CK activity to generate more ATP.

## Conclusion

NaHS administration alone improved rat gastrocnemius response to electric stimulation by increasing peak force production and delaying the onset of 50% fatigue. This could result from ameliorating the oxidative stress response as evidenced by reduced lipid peroxides with consequent improvement of high energy phosphate regeneration. Increased CK activity and decreased lactate concentration is a good proof. Blocking nitric oxide generation by L-NAME produced opposite effects reflecting the importance of NO in EC coupling. Coadministration of NaHS with L-NAME significantly but incompletely corrected the fatiguing effects of L-NAME. This indicated that the antioxidant effects of H<sub>2</sub>S are not NO dependent and there are physiological effects of NO that could not be completely substituted for by H<sub>2</sub>S. The results also reflect the clinical significance of H<sub>2</sub>S donors as a future promising treatment for chronic fatigue syndrome including different myopathies that lack NOS activity.

## References

1. Kent-Braun JA, Fitts RH and Christie A. Skeletal muscle fatigue. *Compr. Physiol.* 2012; 2: 997-1014.
2. Maughan D and Toth M. Discerning Primary and Secondary Factors Responsible for Clinical Fatigue in Multisystem Diseases. *Biology (Basel)*. 2014; 3(3): 707-722.
3. Allen D G, Lamb G D, and Westerblad H. Skeletal Muscle Fatigue: Cellular Mechanisms. *Physiol. Rev.* 2008; 88: 287-332.
4. Newton DJ, Kennedy G, Chan KK, Lang CC, Belch JJ, Khan F. Large and small artery endothelial dysfunction in chronic fatigue syndrome. *Int. J. Cardiol.* 2012; 154: 330-336.
5. Kolluru GK, Shen X and Kevil CG. "A tale of two gases: NO and H<sub>2</sub>S, foes or friends for life?" *Redox Biology.* 2013; 1: 313-318.
6. Shibuya N, Tanaka M and Yoshida M. "γ-Mercaptopyruvate sulfurtransferase

- produces hydrogen sulfide and bound sulfane sulfur in the brain," *Antioxidants & Redox Signaling*. 2009; 11: 103-114
17. Wang Q, Wang XL, Liu HR, Rose P and Zhu YZ. "Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H<sub>2</sub>S production," *Antioxidants & Redox Signaling*. 2010; 12(10): 1100-1110.
  18. Yang GD, Wu LY., Jiang B. "H<sub>2</sub>S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine  $\gamma$ -lyase," *Science*, 2008; 322(5901): 587-590.
  19. Tang G, Wu L and Wang R. "Interaction of hydrogen sulfide with ion channels," *Clinical and Experimental Pharmacology and Physiology*, 2010; 37(7): 703-713.
  20. Wu L, Yang W and Jia, X. "Pancreatic islet overproduction of H<sub>2</sub>S and suppressed insulin release in Zucker diabetic rats," *Laboratory Investigation*, 2009; 89(1): 59-67.
  21. Lu M, Liu YH and Goh HS. "Hydrogen sulfide inhibits plasma renin activity," *Journal of the American Society of Nephrology*, 2010; 21(7): 993-1002.
  22. Lemle D. Hypothesis: Chronic fatigue syndrome is caused by dysregulation of hydrogen sulfide metabolism. *Med. Hypotheses*. 2009; 72: 108-109.
  23. Seneff S. Could Sulfur Deficiency be a Contributing Factor in Obesity, Heart Disease, Alzheimer's and Chronic Fatigue Syndrome? Creative Common (on line), 2010.
  24. Ferraz JG, Tigley A and Wallace JL. Paradoxical effects of L-arginine on gastric mucosal integrity. *Eur. J. Pharmacol.* 1994; 260: 107-111.
  25. Abdollahzade Fard A, Ahangarpour A, Gharibnaseri M, Jalali T, Rashidi I and Ahmadzadeh M. Effects of Hydrogen Sulfide on Oxidative Stress, TNF- $\alpha$  Level and Kidney Histological Changes in Cisplatin Nephrotoxicity in Rat. *J. Phys. Pharm. Adv.* 2013; 3(3): 57-60.
  26. MacIntosh BR and Gardiner PF. Posttetanic potentiation and skeletal muscle fatigue: Interactions with caffeine. *Can. J. Physiol.* 1987; 65: 260-268.
  27. Le-Rumeur E, Le Moyec L and De Cartaines JD. Rat gastrocnemius high and low frequency fatigue without metabolic impairment by <sup>31</sup>P NMR. *Arch. Int. Physiol. Biochem. Biophys.* 1993; 101: 371-376.
  28. Eu JP, Hare JM and Hess DT. Concerted regulation of skeletal muscle contractility by oxygen tension and nitric oxide. *Proc. Natl. Acad. Sci.* 2003; 100: 10229-34.
  29. Dawson T and Dawson V. Nitric oxide: actions and pathological roles. *The Neuroscientist*. 1990; 1(1): 7-18. [DOI: 10.1177/107380849000100103], Quoted from the kit manuscript.
  30. Ohkawa H, Ohishi N and Yagi K. Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal. Biochem.* 1979; 90: 301-308.
  31. Watchko JF, Daood MJ and Labella JJ. Creatine kinase activity in rat skeletal muscle relates to myosin phenotype during development. *Pediatr. Res.* 1996; 40: 53-58
  32. Monica L, Javier N, Alexandra R and Sandra HPF. Skeletal muscle necrosis and regeneration after injection of *Thalassophryne nattereri* (niquim) fish venom in mice. *J Trauma*. 2011; 70(1): 103-110.
  33. Copp SW, Hirai DM, Hageman KS, Poole DC, Musch TI. Nitric oxide synthase inhibition during treadmill exercise reveals fiber-type specific vascular control in the rat hind limb. *Am J Physiol, Regul. Integr. Comp. Physiol.* 2010; 298: R478-R480.
  34. Tidball JG and Wehling-Henricks M. Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy. *J Physiol.* 2014; 592(21): 4727-4738
  35. Baldelli S, Barbato DL, Tatulli G, Aquilano K and Ciriolo MR. The role of nNOS and PGC-1 $\alpha$  in skeletal muscle cells. *Journal of Cell Science*, 2014; 127: 4813-4820. doi:10.1242/jcs.104229

26. McConnell GK, Rattigan S, Lee-Young RS, Wadley GD and Merry TL. Skeletal muscle nitric oxide signaling and exercise: a focus on glucose metabolism. *Am J Physiol. Endocrinol. Metab.* 2012; 303: E301-E307.
27. Mason S and Wadley GD. Skeletal muscle reactive oxygen species: A target of good cop/bad cop for exercise and disease. *Redox Report*, 2014; 19(3): 97-106.
28. Hidalgo C, Sanchez G, Barrientos G and Aracena-Parks P. A transverse tubule NADPH oxidase activity stimulates calcium release from isolated triads via ryanodine receptor type I S-glutathionylation. *J. Biol. Chem.* 2006; 281: 27473-82.
29. Lecarpentier Y. Physiological role of free radicals in skeletal muscles. *Journal of Applied Physiology*, 2007; 103(6): 1917-18.
30. Powers SK, Duarte J, Kavazis AN, and Talbert EE. Reactive oxygen species are signalling molecules for skeletal muscle adaptation. *Exp Physiol.* 2009; 94(1): 1-9.
31. Perevoshchikova IV, Quinlan CL, Orr L, Gerencser AA, Brand MD. Sites of superoxide and hydrogen peroxide production during fatty acid oxidation in rat skeletal muscle mitochondria. *Free Radic. Biol. Med.* 2013; 71: 298-309.
32. Lamb GD and Westerblad H. Acute effects of reactive oxygen and nitrogen species on the contractile function of skeletal muscle. *J. Physiol.* 2011; 589: 2119-2127.
33. Steinbacher P and Eckl P. Impact of Oxidative Stress on Exercising Skeletal Muscle. *Biomolecules*, 2010; 0: 306-327, doi:10.3390/biom0020306
34. Saks V. The phosphocreatine/creatine kinase system helps to shape muscle cells and keep them healthy and alive. *J Physiol.* 2008; 586(12): 2817-2818.
35. Baird ME, Graham SM, Baker JS and Bickerstaff GF. Creatine kinase and exercise related muscle damage implications for muscle performance and recovery. *Journal of Nutrition and Metabolism*, 2012; Vol.2012: 1-13
36. McMullen CA, Katrin, HB and Andrade FH. Fatigue resistance of rat extraocular muscles does not depend on creatine kinase activity. *BMC Physiology*, 2005; 5:12. Doi: 10.1186/1472-7793-5-12.
37. Dahlstedt AJ, Katz A, Wierenga B and Westerblad H. Is creatine kinase responsible for fatigue? Studies of isolated skeletal muscle deficient in creatine kinase. *FASEB J.* 2000; 14: 982-90.
38. Allen DG, Trajanovska S. The multiple roles of phosphate in muscle fatigue. *Front. Physiol.* 2012; 3: 673 10.3389/fphys.2012.00673.
39. Bandschapp O, Soule CHL and Iazzo PA. Lactic acid restores skeletal muscle force in an in vitro fatigue model: are voltage-gated chloride channels involved?. *Am J Physiol Cell Physiol.* 2012; 302(7): C119-C120.
40. Karatzaferi CH and Bryant Chase P. Muscle fatigue and muscle weakness: what we know and what we wish we did. *Frontier Physiol.* 2013; 4: 120.
41. Debold EP. Recent insights into muscle fatigue at the cross-bridge level. *Front. Physiol.* 2012; 3: 101
42. Hey-Mogensen M, Goncalves RL, Orr AL, Brand MD. Production of superoxide/H<sub>2</sub>O<sub>2</sub> by dihydroorotate dehydrogenase in rat skeletal muscle mitochondria. *Free Radic. Biol. Med.* 2014; 72: 149-150.
43. Emilova R, Dimitrova D, Georgiev V, Daneva T and Gagov HS. Cystathionine gamma-lyase as a regulator of resistance artery contraction under normal and hyperglycemic conditions. *Bulgarian Journal of Agricultural Science*, 2013; 19 (2): 170-177
44. Zhang W, Xu CH, Yang G, Wu L and Wang R. Review Article: Interaction of H<sub>2</sub>S with Calcium Permeable Channels and Transporters. *Oxidative Medicine and Cellular Longevity*, 2010; Volume 2010.
45. Henderson PW, Singh SP, Weinstein AL, Nagineni V, Rafii DC, Kadouch D, Krijgh DD and Spector JA. Therapeutic metabolic inhibition: hydrogen sulfide significantly miti-

- gates skeletal muscle ischemia reperfusion injury in vitro and in vivo. *Plast Reconstr Surg.* 2010; 126(7): 1890-8.
26. Du JT, Li W, Yang JY, Tang CS, Li Q and Jin HF. Hydrogen sulfide is endogenously generated in rat skeletal muscle and exerts a protective effect against oxidative stress. *Chin Med J (Engl).* 2013; 126(5): 930-6.
27. Kohn C, Schleifenbaum J, Szijarto IA, Marko L and Dubrovskaja G. Differential Effects of Cystathionine-gamma-lyase-Dependent Vasodilatory H<sub>2</sub>S in Periadventitial Vasoregulation of Rat and Mouse Aortas. *PLoS ONE*, 2012; 7(8): e41901.